The biological-medical focus of CLINSPECT-M revolves around diseases of the nervous system, in particular multiple sclerosis, Alzheimer’s disease, stroke and cancer. Despite their high incidence and social relevance, many aspects of these widespread diseases have so far not been understood. How does multiple sclerosis differ from other neuroinflammatory diseases? Why do some Alzheimer’s patients respond better to drug therapy than others? How can one distinguish ischemic strokes in patients from so-called stroke mimics? Can the proteomic profile of cancer patients help recommend more effective personalized therapies? These and other questions are addressed by the comprehensive interdisciplinary research of the CLINSPECT-M consortium with the help of modern mass spectrometric and bioinformatic approaches.
An outstanding team combining expertise from the fields of medicine, proteomics and bioinformatics want to gain new insights into the underlying pathological processes, want to find molecular signatures that can be used clinically for example as biomarkers for diagnosis, prognosis or treatment response, and want to translate state-of-the-art mass spectrometric and bioinformatic approaches into clinical routine.
